Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy. / Al-Zuhairy, Ali; Jakobsen, Johannes; Moldovan, Mihai; Krarup, Christian.

In: Muscle and Nerve, Vol. 66, No. 6, 2022, p. 715-722.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Al-Zuhairy, A, Jakobsen, J, Moldovan, M & Krarup, C 2022, 'Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy', Muscle and Nerve, vol. 66, no. 6, pp. 715-722. https://doi.org/10.1002/mus.27722

APA

Al-Zuhairy, A., Jakobsen, J., Moldovan, M., & Krarup, C. (2022). Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 66(6), 715-722. https://doi.org/10.1002/mus.27722

Vancouver

Al-Zuhairy A, Jakobsen J, Moldovan M, Krarup C. Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve. 2022;66(6):715-722. https://doi.org/10.1002/mus.27722

Author

Al-Zuhairy, Ali ; Jakobsen, Johannes ; Moldovan, Mihai ; Krarup, Christian. / Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy. In: Muscle and Nerve. 2022 ; Vol. 66, No. 6. pp. 715-722.

Bibtex

@article{dc4d7d89f48c4ba59891538820c5a253,
title = "Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy",
abstract = "Introduction/Aims: We hypothesized that early, pretreatment axonal loss would predict long-term disability, supported by a pilot study of selected patients with chronic inflammatory demyelinating polyneuropathy (CIDP). To further test this hypothesis, we examined a larger consecutive group of CIDP patients. Methods: Needle electromyography and motor and sensory nerve conduction studies were carried out in 30 CIDP patients at pretreatment and follow-up 5 to 28 years later. Changes in amplitudes were expressed as axonal Z scores and changes in conduction as demyelination Z scores and correlated with findings of the Inflammatory Rasch-built Overall Disability Scale (I-RODS), the Neuropathy Impairment Score (NIS), and isokinetic dynamometry (IKS). Results: At follow-up, the median I-RODS score was 73, the NIS was 23, and the IKS was 56%. The median axonal Z score was unchanged at follow-up. Conversely, the corresponding demyelination Z scores improved. The initial axonal loss was correlated with the clinical outcome and was an independent predictor of outcome by multivariate regression analysis. Axonal loss at follow-up was also correlated with the clinical outcome. Only the follow-up demyelination Z score was correlated with the clinical outcomes. Furthermore, the latency until treatment initiation was predictive of all three clinical outcome scores at follow-up, and of axonal loss and demyelination at follow-up. Discussion: The present study findings indicate that pretreatment axonal loss at diagnosis in CIDP is predictive of long-term disability, neurological impairment, and strength. A delay in treatment is associated with more pronounced axonal loss and a worse clinical outcome.",
keywords = "axonal loss, electrophysiological examination, long-term follow-up, prediction of CIDP, prognosis",
author = "Ali Al-Zuhairy and Johannes Jakobsen and Mihai Moldovan and Christian Krarup",
note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.",
year = "2022",
doi = "10.1002/mus.27722",
language = "English",
volume = "66",
pages = "715--722",
journal = "Muscle & Nerve",
issn = "0148-639X",
publisher = "JohnWiley & Sons, Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy

AU - Al-Zuhairy, Ali

AU - Jakobsen, Johannes

AU - Moldovan, Mihai

AU - Krarup, Christian

N1 - Publisher Copyright: © 2022 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.

PY - 2022

Y1 - 2022

N2 - Introduction/Aims: We hypothesized that early, pretreatment axonal loss would predict long-term disability, supported by a pilot study of selected patients with chronic inflammatory demyelinating polyneuropathy (CIDP). To further test this hypothesis, we examined a larger consecutive group of CIDP patients. Methods: Needle electromyography and motor and sensory nerve conduction studies were carried out in 30 CIDP patients at pretreatment and follow-up 5 to 28 years later. Changes in amplitudes were expressed as axonal Z scores and changes in conduction as demyelination Z scores and correlated with findings of the Inflammatory Rasch-built Overall Disability Scale (I-RODS), the Neuropathy Impairment Score (NIS), and isokinetic dynamometry (IKS). Results: At follow-up, the median I-RODS score was 73, the NIS was 23, and the IKS was 56%. The median axonal Z score was unchanged at follow-up. Conversely, the corresponding demyelination Z scores improved. The initial axonal loss was correlated with the clinical outcome and was an independent predictor of outcome by multivariate regression analysis. Axonal loss at follow-up was also correlated with the clinical outcome. Only the follow-up demyelination Z score was correlated with the clinical outcomes. Furthermore, the latency until treatment initiation was predictive of all three clinical outcome scores at follow-up, and of axonal loss and demyelination at follow-up. Discussion: The present study findings indicate that pretreatment axonal loss at diagnosis in CIDP is predictive of long-term disability, neurological impairment, and strength. A delay in treatment is associated with more pronounced axonal loss and a worse clinical outcome.

AB - Introduction/Aims: We hypothesized that early, pretreatment axonal loss would predict long-term disability, supported by a pilot study of selected patients with chronic inflammatory demyelinating polyneuropathy (CIDP). To further test this hypothesis, we examined a larger consecutive group of CIDP patients. Methods: Needle electromyography and motor and sensory nerve conduction studies were carried out in 30 CIDP patients at pretreatment and follow-up 5 to 28 years later. Changes in amplitudes were expressed as axonal Z scores and changes in conduction as demyelination Z scores and correlated with findings of the Inflammatory Rasch-built Overall Disability Scale (I-RODS), the Neuropathy Impairment Score (NIS), and isokinetic dynamometry (IKS). Results: At follow-up, the median I-RODS score was 73, the NIS was 23, and the IKS was 56%. The median axonal Z score was unchanged at follow-up. Conversely, the corresponding demyelination Z scores improved. The initial axonal loss was correlated with the clinical outcome and was an independent predictor of outcome by multivariate regression analysis. Axonal loss at follow-up was also correlated with the clinical outcome. Only the follow-up demyelination Z score was correlated with the clinical outcomes. Furthermore, the latency until treatment initiation was predictive of all three clinical outcome scores at follow-up, and of axonal loss and demyelination at follow-up. Discussion: The present study findings indicate that pretreatment axonal loss at diagnosis in CIDP is predictive of long-term disability, neurological impairment, and strength. A delay in treatment is associated with more pronounced axonal loss and a worse clinical outcome.

KW - axonal loss

KW - electrophysiological examination

KW - long-term follow-up

KW - prediction of CIDP

KW - prognosis

U2 - 10.1002/mus.27722

DO - 10.1002/mus.27722

M3 - Journal article

C2 - 36217677

AN - SCOPUS:85140469874

VL - 66

SP - 715

EP - 722

JO - Muscle & Nerve

JF - Muscle & Nerve

SN - 0148-639X

IS - 6

ER -

ID: 323921139